Title: The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.  
Lead Author: Hans Gelderblom
Abstract: 11504
Oral presentation: Saturday, May 30, 2026 (Session time: 4:12 PM – 4:24 PM CDT)

Title: Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). 
Lead Author: Hazel Lote
Abstract: 3533
Poster presentation: Saturday, May 30, 2026 (Session time: 9:00 AM – 12:00 PM CDT)

ASCO 2026_ChonDRAgon Secondary Endpoints_Abstract

167 KB

ASCO 2026_Ozekibart in CRC Updated Data_Abstract

150 KB

ASCO 2026_INBRX-109 CRC Data Update_Poster_Lote

1.8 MB

ASCO 2026_ChonDRAgon Secondary Endpoints_Oral Presentation_Gelderblom

902 KB